C. Hesse

发表

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

K. Blennow, B. Winblad, H. Vanderstichele, 1999, Archives of neurology.

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2000, Journal of Alzheimer's disease : JAD.

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

K. Blennow, E. Vanmechelen, I. Skoog, 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

K. Blennow, C. Hesse, P. Fredman, 1994, Neuroreport.

Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform.

K. Blennow, A. Wallin, M. Landén, 1996, Dementia.

The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis.

K. Blennow, H. Zetterberg, N. Mattsson, 2011, Biochemical and biophysical research communications.

Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two‐dimensional electophoresis approach prior to mass spectrometry

K. Blennow, C. Nilsson, C. Hesse, 2001, Proteomics.

A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality

K. Blennow, I. Skoog, C. Hesse, 1998, Journal of neurology, neurosurgery, and psychiatry.

Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke.

K. Blennow, C. Hesse, P. Davidsson, 2001, Journal of Alzheimer's disease : JAD.

Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two‐dimensional electrophoresis and matrix assisted laser desorption/ionization‐time of flight‐mass spectrometry

K. Blennow, C. Hesse, P. Davidsson, 2001, Electrophoresis.

Human Urinary Glycoproteomics; Attachment Site Specific Analysis of N- and O-Linked Glycosylations by CID and ECD*

Jonas Nilsson, Göran Larson, Adnan Halim, 2011, Molecular & Cellular Proteomics.

Enrichment of glycopeptides for glycan structure and attachment site identification

C. Hesse, G. Larson, G. Brinkmalm, 2009, Nature Methods.

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2001, Neuroscience Letters.

Clusterin (Apolipoprotein J) Protein Levels Are Increased in Hippocampus and in Frontal Cortex in Alzheimer's Disease

K. Blennow, N. Bogdanovic, C. Hesse, 1998, Experimental Neurology.

Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma

K. Blennow, H. Vanderstichele, L. Minthon, 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

The apolipoprotein E ϵ4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease

K. Blennow, L. Minthon, M. Sjögren, 1997, Neuroscience Letters.

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study

K. Blennow, B. Winblad, E. Vanmechelen, 1998, Journal of neurology, neurosurgery, and psychiatry.

Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype

K. Blennow, L. Minthon, Å. Edman, 2001, Journal of Neural Transmission.

A population study on blood-brain barrier function in 85-year-olds

K. Blennow, A. Wallin, I. Skoog, 1998, Neurology.

No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression

K. Blennow, A. Brookes, L. Minthon, 2000, Journal of Neural Transmission.

Measurement of Apolipoprotein E (apoE) in Cerebrospinal Fluid

Kaj Blennow, Lennart Minthon, Pam Fredman, 2000, Neurochemical Research.

A Quantitative and Immunohistochemical Study on Apolipoprotein E in Brain Tissue in Alzheimer’s Disease

K. Blennow, N. Bogdanovic, C. Hesse, 1999, Dementia and Geriatric Cognitive Disorders.

Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions.

I. Skoog, C. Hesse, P. Fredman, 1997, Archives of neurology.

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

Kaj Blennow, Lennart Minthon, K. Blennow, 2001, Neuroscience Letters.

The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis.

K. Blennow, H. Zetterberg, N. Mattsson, 2011, Biochemical and biophysical research communications.